Potassium canrenoate

Potassium canrenoate
Clinical data
Other names	SC-14266
AHFS/Drugs.com	International Drug Names
Routes of; administration	Intravenous
ATC code	C03DA02 (WHO) ;
Pharmacokinetic data
Metabolism	Hepatic
Excretion	Renal and fecal
Identifiers
	IUPAC name potassium 3-[(8R,9S,10R,13S,14S,17R)-; 17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,; 11,12,14,15,16-octahydro-1H-cyclopenta[a]; phenanthren-17-yl]propanoate;
CAS Number	2181-04-6 ;
PubChem CID	23671691;
DrugBank	DB09015 ;
ChemSpider	570975 ;
UNII	M671F9NLEA;
ChEMBL	ChEMBL1371200 ;
CompTox Dashboard (EPA)	DTXSID2045602 ;
ECHA InfoCard	100.016.868
Chemical and physical data
Formula	C22H29KO4
Molar mass	396.568 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [K+].[O-]C(=O)CC[C@]3(O)CC[C@H]2[C@@H]4/C=C\C1=C\C(=O)CC[C@@]1([C@H]4CC[C@@]23C)C;
	InChI InChI=1S/C22H30O4.K/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25;/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25);/q;+1/p-1/t16-,17+,18+,20+,21+,22-;/m1./s1 ; Key:JTZQCHFUGHIPDF-RYVBEKKQSA-M ;
	(verify)

Potassium canrenoate (INN, JAN) or canrenoate potassium (USAN) (brand names Venactone, Soldactone), also known as aldadiene kalium,^[1] the potassium salt of canrenoic acid, is an aldosterone antagonist of the spirolactone group.^[2] Like spironolactone, it is a prodrug, and is metabolized to active canrenone in the body.^[3]^[4]

Potassium canrenoate is notable in that it is the only clinically used antimineralocorticoid which is available for parenteral administration (specifically intravenous)^[4]^[5] as opposed to oral administration.^[6]

References

^ Hans Selye (17 April 2013). Hormones and Resistance: Part 1 and. Springer Science & Business Media. pp. 186–. ISBN 978-3-642-65192-2.
^ R.A. Hill; H.L.J. Makin; D.N. Kirk; G.M. Murphy (23 May 1991). Dictionary of Steroids. CRC Press. pp. 656–. ISBN 978-0-412-27060-4.
^ Alfred Burger; Manfred E. Wolff (1996). Burger's Medicinal Chemistry and Drug Discovery: Therapeutic agents. Wiley. ISBN 978-0-471-57557-3.
^ ^a ^b Carl Waldmann; Neil Soni; Andrew Rhodes (27 November 2008). Oxford Desk Reference: Critical Care. OUP Oxford. pp. 187–. ISBN 978-0-19-922958-1.
^ H. Jaap Bonjer (21 June 2017). Surgical Principles of Minimally Invasive Procedures: Manual of the European Association of Endoscopic Surgery (EAES). Springer. pp. 136–. ISBN 978-3-319-43196-3.
^ Kolkhof P, Bärfacker L (2017). "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". J. Endocrinol. 234 (1): T125–T140. doi:10.1530/JOE-16-0600. PMC 5488394. PMID 28634268.

[Selye2013-1] Hans Selye (17 April 2013). Hormones and Resistance: Part 1 and. Springer Science & Business Media. pp. 186–. ISBN 978-3-642-65192-2.

[HillMakin1991-2] R.A. Hill; H.L.J. Makin; D.N. Kirk; G.M. Murphy (23 May 1991). Dictionary of Steroids. CRC Press. pp. 656–. ISBN 978-0-412-27060-4.

[BurgerWolff1996-3] Alfred Burger; Manfred E. Wolff (1996). Burger's Medicinal Chemistry and Drug Discovery: Therapeutic agents. Wiley. ISBN 978-0-471-57557-3.

[WaldmannSoni2008-4] Carl Waldmann; Neil Soni; Andrew Rhodes (27 November 2008). Oxford Desk Reference: Critical Care. OUP Oxford. pp. 187–. ISBN 978-0-19-922958-1.

[Bonjer2017-5] H. Jaap Bonjer (21 June 2017). Surgical Principles of Minimally Invasive Procedures: Manual of the European Association of Endoscopic Surgery (EAES). Springer. pp. 136–. ISBN 978-3-319-43196-3.

[pmid28634268-6] Kolkhof P, Bärfacker L (2017). "30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development". J. Endocrinol. 234 (1): T125–T140. doi:10.1530/JOE-16-0600. PMC 5488394. PMID 28634268.

[1]

[2]

[3]

[4]

[5]

[6]

Potassium canrenoate

See also

References